A First-in-Human, Open-Label, Multi-Center Phase 1 Study of TST003 in Subjects with Locally Advanced or Metastatic Solid Tumors

MC #23-02

NCT #
NCT05731271
Condition(s)
Breast Cancer, Colorectal Cancer, Esophageal Cancer, Gastric/GEJ Cancer, Lung Cancer (NSCLC), Prostate Cancer, Solid Tumor
Molecular Target(s)
GREM1
Drug Classification(s)
Monoclonal Antibody
Agents(s)
NCT05941507
Phase(s)
I

Mechanism of Action

anti-GREM1 monoclonal antibody

Purpose

  • How much of the study agent can be given with an acceptable level of side effects
  • The effects of the study agent (good and bad)
  • How much of the study agent is absorbed into the blood and how fast it is removed
  • How the study agent is acting on your body

Location

MCD

Connect With Us

Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.